The Chief Business Officer leads external strategy – licensing deals, identifying pharma partnerships, and developing long-term growth planning and market positioning strategies that maximize the impact of scientific breakthroughs. 

They often represent the company in M&A conversations, investor pitches, and business development meetings. From which they can feedback critical market intelligence to help shape internal research priorities and clinical development strategies. 

In order to be successful, a CBO needs to be able to rely on more than just great science – they need credible execution. 

If a trial is behind on its recruitment targets, that risk shows up in deal terms, timelines, and investor confidence. 

Which is why recruitment staying on track – evidenced by detailed enrollment projections and contingency planning details as provided by the recruitment leads – helps the CBO make the case convincingly that internal momentum can be translated into external value.